Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 1: 88 - 94

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231121.002

Original articles

Efficacy of Jiangzhi Xiaoban tablet (降脂消斑片) on toll-like receptor 4/nuclear factor-kappa B/nod-like receptor protein 3 signaling pathway in mice with atherosclerosis induced by high-fat diet

  • Huihui LIU ,
  • Jun FENG ,
  • Jianhe LIU ,
  • Choufu CHENG ,
  • Guoheng HU
Expand
  • 1 Hunan University of Chinese Medicine, Changsha 410208, China
    2 Department of Geriatrics, the First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
    3 Department of Cardiology, the First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
    4 Department of Neurology, the First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China

Received date: 2022-11-02

  Accepted date: 2023-02-02

  Online published: 2023-11-21

Supported by

Youth Fund Project of Hunan Natural Science Foundation Committee: to Explore the Protective Effect of Chaihu Sanshen Capsule on Myocardial Ischemia Reperfusion Injury Based on Iron Death and Inflammatory Response of Myocardial Cells Induced by Mixed lineage kinase 3 Signaling Pathway(2021JJ40419);Traditional Chinese Medicine Administration of Hunan Province: to Explore the Mechanism of the Protective Effect of Chaihu Sanshen Capsule on Myocardial Ischemia Reperfusion Injury based on MicroRNA-145-5p Inhibition of Iron Death and Inflammatory Response of Myocardial Cells Induced by Mixed Lineage Kinase 3 Signaling Pathway(B2023019);Health Commission of Hunan Province: to Explore the Mechanism of Chaihu Sanshen Capsule in Reducing Myocardial Ischemia Reperfusion Injury Based on Nuclear Factor Erythroid 2-related Factor 2/Heme Oxygenase-1 Pathway Inhibiting Iron Death of Myocardial Cells(2021116001377);Hunan University of Chinese Medicine: To Explore the Intervention Effect of Zhenwu Decoction on the Model of Heart and Kidney Yang Deficiency in Rats with Cardiorenal Syndrome through MicroRNA-214/Receptor-interacting Protein Kinase 1-mediated Tumor Necrosis Factor Signal Pathway(2020XJJJ038)

Fold

Abstract

OBJECTIVE: To study the effect of Jiangzhi Xiaoban tablet (降脂消斑片, JZXB) on toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB)/Nod-like receptor protein 3 (NLRP3) signaling pathway expression in atherosclerosis (AS) mice by establishing a mouse model of AS, and to explore its mechanism of prevention and treatment of AS.

METHODS: Sixty-four male C57BL/6J mice were randomly divided into two groups, 12 in the normal control group and 52 in the model group (MOD). Seven weeks later, two mice in each of the above two groups were randomly sacrificed, and the whole aortic tissue of the mice was taken out for hematoxylin-eosin staining. After successful modeling, 50 mice in the modeling group were randomly divided into 5 groups: MOD, atorvastatin group (ATO), low-dose group of JZXB (JZXB-L), middle-dose group of JZXB (JZXB-M), and high-dose group of JZXB (JZXB-H), 10 mice in each group. The mice in each group were killed after 6 weeks of preventive administration. HE staining was used to observe the pathological changes of aorta in AS mice. The levels of serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were detected by automatic biochemical analyzer. The levels of inflammatory factor interleukin-1β (IL-1β) were detected by enzyme linked immunosorbent assay. The expression of TLR4, NF-κB and NLRP3 proteins in aortic tissue was detected by immunohistochemistry.

RESULTS: Compared with the MOD, the levels of serum TC, TG and LDL-C in the JZXB-H and ATO were significantly decreased, while the level of HDL-C was significantly increased. The levels of serum TG, LDL-C in the JZXB-M were significantly decreased, and the level of HDL-C was significantly increased. Compared with the MOD, the levels of IL-1β were significantly decreased, aortic lesions were significantly improved, and the expression of TLR4, NF-κB, and NLRP3 proteins in the aortic tissue was significantly decreased in the JZXB-H, JZXB-M, and ATO.

CONCLUSION: JZXB has inhibitory effect on atherosclerosis in mice, and its mechanism may be through regulating the TLR4/NF-κB/NLRP3 signaling pathway and reducing the inflammatory response, so as to play a role in inhibiting atherosclerosis.

Key words： atherosclerosis; toll-like receptor 4; NF-kappa B; NLR proteins; signal transduction; inflammation; Jiangzhi Xiaoban tablet

Cite this article

Huihui LIU , Jun FENG , Jianhe LIU , Choufu CHENG , Guoheng HU . Efficacy of Jiangzhi Xiaoban tablet (降脂消斑片) on toll-like receptor 4/nuclear factor-kappa B/nod-like receptor protein 3 signaling pathway in mice with atherosclerosis induced by high-fat diet[J]. Journal of Traditional Chinese Medicine, 2024 , 44(1) : 88 -94 . DOI: 10.19852/j.cnki.jtcm.20231121.002

References

1. Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China). Circulation 2016; 134: 1430-40.
2. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004-13.
3. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res 2019; 124: 315-27.
4. Welsh P, Grassia G, Botha S, et al. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017; 174: 3898-913.
5. Chistiakov DA, Bobryshev YV, Nikiforov NG, et al. Macrophage phenotypic plasticity in atherosclerosis: the associated features and the peculiarities of the expression of inflammatory genes. Int J Cardiol 2015; 184: 436-445.
6. Chen KJ. Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy. Chin J Integr Med 2012; 18: 891-6.
7. Zheng LY, Fang XM. A brief introduction to the treatment of acute coronary syndrome by promoting blood circulation and removing blood stasis. Shi Yong Zhong Yi Nei Kei Za Zhi 2016; 30: 116-8.
8. Wang YA, Yang L, Yu XJ, et al. Observation on the effect of Jiangzhi Xiaoban tablet on improving cardiac function in patients with coronary heart disease. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2015; 13: 1822-4.
9. Wu J, Cheng CF. The effect of Jiangzhi Xiaoban tablet assisted with conventional Western Medicine treatment on coronary plaques and inflammatory factors in coronary heart disease and angina pectoris. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2018; 25: 25-9.
10. Li PC, Cheng CF, Lu LL, et al. The effect of Jiangzhi Xiaoban tablet on VEGF-mediated inflammation in AS plaques. Zhong Yi Yao Xin Xi 2014; 31: 102-6.
11. Zhao Y, Qu H, Wang Y, et al. Small rodent models of atherosclerosis. Biomed Pharmacother 2020; 129: 110426.
12. Peled M, Nishi H, Weinstock A, et al. A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS One 2017; 12: e0173975.
13. The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Summary of China cardiovascular health and disease report 2020. Zhong Guo Xun Huan Za Zhi 2021; 36: 521-45.
14. The Writing Committee of the Report on Cardiovascular Health Diseases in China. Summary of China cardiovascular health and disease report 2019. Zhong Guo Xun Huan Za Zhi 2020; 35: 833-54.
15. Hu SS, Gao RL, Liu LS, et al. Summary of "Chinese cardiovascular disease report 2018". Zhong Guo Xun Huan Za Zhi 2019; 34: 209-20.
16. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation 2017; 135: e146-603.
17. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867-79.
18. Li HM, Wang X. Research progress on the correlation between TLR4/MyD88/NF-κB signaling pathway and atherosclerotic cardiovascular disease. Zhong Guo Xun Zheng Xin Xue Guan Yi Xue Za Zhi 2017; 9: 1132-4.
19. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-86.
20. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018; 269: 262-71.
21. Zhang H, Gong X, Ni S, et al. C1q/TNF-related protein-9 attenuates atherosclerosis through AMPK-NLRP 3 inflammasome singling pathway. Int Immunopharmacol 2019; 77: 105934.
22. Luo J, Wang X, Jiang X, et al. Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport. FASEB J 2020; 34: 1398-411.
23. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183: 787-91.
24. Xue Y, Enosi Tuipulotu D, Tan WH, et al. Emerging activators and regulators of inflammasomes and pyroptosis. Trends Immunol 2019; 40: 1035-52.
25. Stitham J, Rodriguez-Velez A, Zhang X, et al. Inflammasomes: a preclinical assessment of targeting in atherosclerosis. Expert Opin Ther Targets 2020; 24: 825-44.
26. Jiang SG, Cheng CF. Clinical observation of Jiangzhi Xiaoban tablet in the treatment of 30 cases of phlegm and blood stasis syndrome of hyperlipidemia. Zhong Yi Yao Dao Bao 2011; 17: 20-2.
Options
Outlines

/

〈 〉